Mavacamten

{{Short description|Chemical compound}}

{{Use American English|date=April 2022}}

{{Use dmy dates|date=June 2023}}

{{Infobox drug

| image = Mavacamten.svg

| width =

| alt =

| caption =

| pronounce =

| tradename = Camzyos

| Drugs.com = {{drugs.com|monograph|mavacamten}}

| MedlinePlus = a622047

| DailyMedID = Mavacamten

| image_class = skin-invert-image

| pregnancy_AU = D

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = By mouth

| class = Cardiac myosin inhibitor

| ATC_prefix = C01

| ATC_suffix = EB24

| ATC_supplemental =

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Camzyos | publisher=Therapeutic Goods Administration (TGA) | date=13 October 2022 | url=https://www.tga.gov.au/resources/auspmd/camzyos | access-date=28 April 2023 | archive-date=5 February 2023 | archive-url=https://web.archive.org/web/20230205203431/https://www.tga.gov.au/resources/auspmd/camzyos | url-status=live }}{{cite web | title=Camzyos (Bristol-Myers Squibb Australia Pty Ltd) | publisher=Therapeutic Goods Administration (TGA) | date=7 October 2022 | url=https://www.tga.gov.au/resources/prescription-medicines-registrations/camzyos-bristol-myers-squibb-australia-pty-ltd | access-date=28 April 2023 | archive-date=13 November 2022 | archive-url=https://web.archive.org/web/20221113202648/https://www.tga.gov.au/resources/prescription-medicines-registrations/camzyos-bristol-myers-squibb-australia-pty-ltd | url-status=live }}

| legal_BR = C1

| legal_BR_comment = {{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2023-04-04}}

| legal_CA = Rx-only

| legal_CA_comment = {{cite web | title=Camzyos Product information | website=Health Canada | url=https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=102157 | access-date=2 January 2023 | archive-date=3 January 2023 | archive-url=https://web.archive.org/web/20230103054116/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=102157 | url-status=live }}{{cite web | title=Summary Basis of Decision for Camzyos | website=Health Canada | date=12 April 2023 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1684173887386 | access-date=5 June 2023 | archive-date=3 August 2023 | archive-url=https://web.archive.org/web/20230803054858/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1684173887386 | url-status=live }}{{cite web | title=Details for: Camzyos | website=Health Canada | date=9 January 2023 | url=https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102157 | access-date=3 March 2024 | archive-date=3 March 2024 | archive-url=https://web.archive.org/web/20240303062051/https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102157 | url-status=live }}

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Camzyos- mavacamten capsule, gelatin coated | website=DailyMed | date=28 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b | access-date=15 May 2022 | archive-date=3 July 2022 | archive-url=https://web.archive.org/web/20220703055430/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=669c936b-3ee6-4e36-8a22-79dd11b1255b | url-status=live }}

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=Camzyos EPAR | website=European Medicines Agency (EMA) | date=24 July 2023 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos | access-date=2 August 2023 | archive-date=3 August 2023 | archive-url=https://web.archive.org/web/20230803055208/https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos | url-status=live }}

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1642288-47-8

| CAS_supplemental =

| PubChem = 117761397

| IUPHAR_ligand =

| DrugBank = DB14921

| ChemSpiderID =

| UNII = QX45B99R3J

| KEGG = D12265

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = MYK-461

| IUPAC_name = 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione

| C = 15 | H = 19 | N = 3 | O = 2

| SMILES = CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O

| StdInChI = 1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1

| StdInChI_comment =

| StdInChIKey = RLCLASQCAPXVLM-NSHDSACASA-N

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.

Mavacamten is a small-molecule allosteric {{cite journal | vauthors = Edelberg JM, Sehnert AJ, Mealiffe ME, Del Rio CL, McDowell R | title = The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review | journal = American Journal of Cardiovascular Drugs | volume = 22 | issue = 5 | pages = 497–510 | date = September 2022 | pmid = 35435607 | pmc = 9467968 | doi = 10.1007/s40256-022-00532-x }} and cardiac myosin inhibitor. It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb.{{cite press release | title=Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise | publisher=Bristol Myers Squibb | via=Business Wire | date=17 November 2020 | url=https://www.businesswire.com/news/home/20201117005811/en/Bristol-Myers-Squibb-Completes-Acquisition-of-MyoKardia-Strengthening-Company%E2%80%99s-Leading-Cardiovascular-Franchise | access-date=29 April 2022 | archive-date=29 April 2022 | archive-url=https://web.archive.org/web/20220429175608/https://www.businesswire.com/news/home/20201117005811/en/Bristol-Myers-Squibb-Completes-Acquisition-of-MyoKardia-Strengthening-Company%E2%80%99s-Leading-Cardiovascular-Franchise | url-status=live }} In clinical studies, mavacamten has demonstrated significant efficacy in reducing cardiac muscle contractility by targeting the sarcomere hypercontractility that is one of the characteristics of hypertrophic cardiomyopathy and inhibits excessive myosin actin cross-bridge formation, shifting the overall myosin population towards an energy-sparing, recruitable, super-relaxed state.

Mavacamten was approved for medical use in the United States in April 2022.{{cite press release |url=https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition |title=FDA approves new drug to improve heart function in adults with rare heart condition |publisher=U.S. Food and Drug Administration (FDA) |date=29 April 2022 |access-date=29 November 2022 |archive-date=29 November 2022 |archive-url=https://web.archive.org/web/20221129094909/https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition |url-status=live }}{{cite news |url=https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-bristol-myers-heart-disease-drug-2022-04-29/ |title=FDA approves Bristol Myers' oral heart disease drug |work=Reuters |date=29 April 2022 |access-date=29 November 2022 |archive-date=29 November 2022 |archive-url=https://web.archive.org/web/20221129094908/https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-bristol-myers-heart-disease-drug-2022-04-29/ |url-status=live }}{{cite press release | title=U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms | publisher=Bristol Myers Squibb | via=Business Wire | date=28 April 2022 | url=https://www.businesswire.com/news/home/20220428006368/en | access-date=29 April 2022 | archive-date=29 April 2022 | archive-url=https://web.archive.org/web/20220429002313/https://www.businesswire.com/news/home/20220428006368/en/ | url-status=live }} The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite web | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2022 | website=U.S. Food and Drug Administration (FDA) | date=10 January 2023 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | access-date=22 January 2023 | archive-date=21 January 2023 | archive-url=https://web.archive.org/web/20230121035714/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | url-status=dead }} {{PD-notice}}{{cite report | title=New Drug Therapy Approvals 2022 | website=U.S. Food and Drug Administration (FDA) | date=January 2024 | url=https://www.fda.gov/media/164429/download | format=PDF | access-date=14 January 2024 | archive-url=https://web.archive.org/web/20240114065648/https://www.fda.gov/media/164429/download | archive-date=14 January 2024 | url-status=dead }} {{PD-notice}}